Sensitive and specific serodiagnosis of Leishmania infantum infection in dogs by using peptides selected from hypothetical proteins identified by an immunoproteomic approach by Chávez-Fumagalli, Miguel A. et al.
Sensitive and Specific Serodiagnosis of Leishmania infantum Infection
in Dogs by Using Peptides Selected from Hypothetical Proteins
Identified by an Immunoproteomic Approach
Miguel A. Chávez-Fumagalli,a Vivian T. Martins,b Miriam C. S. Testasicca,c Daniela P. Lage,d Lourena E. Costa,a Paula S. Lage,a
Mariana C. Duarte,a Henrique G. Ker,e Tatiana G. Ribeiro,c Fernando A. A. Carvalho,f Wiliam C. B. Régis,g Alexandre B. dos Reis,e
Carlos A. P. Tavares,b Manuel Soto,h Ana Paula Fernandes,i Eduardo A. F. Coelhoa,d
Programa de Pós-Graduação em Ciências da Saúde, Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas
Gerais, Brazila; Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazilb;
Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazilc;
Departamento de Patologia Clínica, COLTEC, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazild; Departamento de Análises Clínicas, Escola de
Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazile; Departamento de Bioquímica e Farmacologia, Centro de Ciências da Saúde, Universidade
Federal do Piauí, Teresina, Piauí, Brazilf; PUC Minas and Minasfungi do Brasil Ltda., Belo Horizonte, Minas Gerais, Brazilg; Centro de Biología Molecular Severo Ochoa, CSIC-
UAM, Departamento de Biología Molecular, Universidad Autónoma de Madrid, Madrid, Spainh; Departamento de Análises Clínicas e Toxicológicas, Faculdade de
Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazili
In Brazil, the percentage of infected dogs living in areas where canine visceral leishmaniasis (CVL) is endemic ranges from 10 to
62%; however, the prevalence of infection in dogs is probably higher than figures reported from serological studies. In addition,
problems with the occurrence of false-positive or false-negative results in the serodiagnosis of CVL have been reported. The
present work analyzed the potential of synthetic peptides mapped from hypothetical proteins for improvement of the serodiag-
nosis of Leishmania infantum infection in dogs. From 26 identified leishmanial proteins, eight were selected, considering that no
homologies between these proteins and others from trypanosomatide sequence databases were encountered. The sequences of
these proteins were mapped to identify linear B-cell epitopes, and 17 peptides were synthesized and tested in enzyme-linked im-
munosorbent assays (ELISAs) for the serodiagnosis of L. infantum infection in dogs. Of these, three exhibited sensitivity and
specificity values higher than 75% and 90%, respectively, to differentiate L. infantum-infected animals from Trypanosoma cruzi-
infected animals and healthy animals. Soluble Leishmania antigen (SLA) showed poor sensitivity (4%) and specificity (36%) to
differentiate L. infantum-infected dogs from healthy and T. cruzi-infected dogs. Lastly, the three selected peptides were com-
bined in different mixtures and higher sensitivity and specificity values were obtained, even when sera from T. cruzi-infected
dogs were used. The study’s findings suggest that these three peptides can constitute a potential tool for more sensitive and spe-
cific serodiagnosis of L. infantum infection in dogs.
The leishmaniases consist of a wide range of diseases present in88 countries, with 12 million people infected and 350 million
at risk of infection (1). Zoonotic visceral leishmaniasis is a severe
disease caused by Leishmania infantum in the Mediterranean area,
the Middle East, Africa, Asian countries, and Latin America (2, 3).
The disease also is emergent in dogs living in the United States,
Canada, northern Italy, and Germany (4–6). In Brazil, the disease
is caused by Leishmania chagasi (syn. L. infantum), with the para-
sites being transmitted by Lutzomyia longipalpis and Lutzomyia
cruzi and wild and domestic canids representing the main reser-
voirs of parasites (7).
Upon infection, dogs develop asymptomatic or symptomatic
clinical forms of disease (8–10). Serological tests used for symp-
tomatic canine visceral leishmaniasis (CVL) diagnosis are facili-
tated by the strong humoral response that generally accompanies
the development of acute disease (11, 12). Courtenay et al. (13)
showed that a high percentage of asymptomatic dogs developed
symptoms after some months and that those dogs were able to
infect about 99.6% of sandflies. In this context, in areas in which
CVL is endemic, about 10 to 62% of apparently healthy and/or
seronegative dogs are positive for Leishmania by PCR (14–17).
Thus, asymptomatic dogs, which play a role in the transmission of
parasites, are not detected by conventional serological tests, such
as the indirect fluorescent antibody test (IFAT) and the enzyme-
linked immunosorbent assay (ELISA) (18). Nonetheless, the de-
tection of asymptomatic CVL might be crucial in controlling ep-
idemics and avoiding the spread of disease among dogs, as well as
between dogs and human populations (19, 20).
There are areas of endemicity where transmission of Leishma-
nia spp. and Trypanosoma cruzi parasites are superposed and, due
to the phylogenetic similarity between those parasites, serological
cross-reactions and/or false-positive results are quite common
(21, 22). As a strategy to develop a more sensitive and specific
method for serodiagnosis of CVL, some individual Leishmania
proteins were used as recombinant antigens (23, 24). However,
due to the high variability observed in the humoral responses of
infected dogs, efficient diagnosis based on purified antigens might
require a mixture of antigens or the use of chimeric antigens con-
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taining several leishmanial proteins (25). One alternative means
to identify sensitive and specific antigens for the diagnosis of CVL
is through the use of synthetic peptides. These antigens are rela-
tively simpler and cheaper to produce than recombinant proteins.
It also has been reported that the use of synthetic peptides (indi-
vidually or in a mixture format), in comparison with the use of
recombinant proteins, is able to increase the sensitivity and/or
specificity of immunoassays for the serodiagnosis of parasitic
diseases (26), such as canine and human visceral leishmaniasis
(27, 28).
In an attempt to identify more-refined antigens for the serodi-
agnosis of CVL, 26 hypothetical proteins from L. infantum, which
were identified previously by means of an immunoproteomic ap-
proach (29), were evaluated in this study. Of the hypothetical
leishmanial proteins investigated, eight were identified as Leish-
mania-specific proteins. Therefore, the present study sought to
map B-cell epitopes from these eight antigens and to use their
corresponding peptides for improvement of the sensitivity and
specificity of the serodiagnosis of L. infantum infection in dogs.
MATERIALS AND METHODS
Ethics statement. Experiments were performed in compliance with na-
tional guidelines for institutional animal care, and the Committee on the
Ethical Handling of Research Animals from the Federal University of
Minas Gerais approved this study (protocol number 043/2011). Serum
samples were kindly provided by Alexandre Barbosa dos Reis, Maria
Norma Melo (Department of Parasitology, Institute of Biological Sci-
ences, Federal University of Minas Gerais, Belo Horizonte, Brazil), and
Fernando Aécio de Amorim Carvalho.
Parasites. Leishmania infantum (strain MOM/BR/1970/BH46) was
grown at 24°C in Schneider’s medium (Sigma, St. Louis, MO) supple-
mented with 20% heat-inactivated fetal bovine serum (Sigma), 20 mM
L-glutamine, 200 U/ml penicillin, and 100g/ml streptomycin, at pH 7.4.
Parasites were provided by Maria Norma Melo.
Antigen preparation. Soluble Leishmania antigen (SLA) extract was
prepared from stationary-phase promastigotes of L. infantum, as de-
scribed previously (30). Briefly, 1  1010 parasites were washed three
times in cold sterile phosphate-buffered saline (PBS). After seven cycles of
freezing (196°C) and thawing (37°C), followed by ultrasonication (Ul-
trasonic processor, GEX600) with five cycles of 30 s at 38 MHz, the sus-
pension was centrifuged at 8,000 g for 30 min at 4°C, and the superna-
tant containing SLA was collected. The protein concentration was
estimated by the Bradford method (31), and aliquots were stored at
80°C until use.
Serum samples. Serum samples used in this study were obtained from
the area of Belo Horizonte, Minas Gerais, Brazil, in which CVL is endemic.
Sera of dogs with CVL were selected on the basis of two serological tests
(IFAT [Bio-Manguinhos IFAT-LVC kit] and ELISA [Bio-Manguinhos
EIE-LVC kit], both from Bio-Manguinhos, Fiocruz, Brazil) for Leishma-
nia spp. Dogs with IFAT titers of less than 1:40 or ELISA reactivity below
the cutoff value indicated by the manufacturer were considered to be
seronegative. Animals with IFAT titers of more than 1:40 and ELISA val-
ues over the cutoff were considered to be seropositive and infected with
Leishmania spp. Thus, symptomatic dogs were those positive by IFAT and
ELISA and also parasite positive by PCR-restriction fragment length poly-
morphism (RFLP) testing in blood samples and presenting more than
three clinical symptoms (weight loss, alopecia, adenopathy, onychogry-
phosis, hepatomegaly, conjunctivitis, and exfoliative dermatitis on the
nose, tail, and ear tips). The asymptomatic dogs were seronegative by
IFAT and ELISA but were positive by PCR-RFLP assay in blood samples.
Healthy dogs were selected from an area of Belo Horizonte in which CVL
is endemic, were considered negative based on molecular (PCR assay in
blood samples) and serological (IFAT and ELISA) testing, and were clin-
ically free of symptoms. Regarding the T. cruzi-infected animals, 19 ani-
mals selected in an area with endemic leishmaniasis (Minas Gerais, Brazil)
were inoculated intraperitoneally with metacyclic trypomastigote forms
of T. cruzi strain Be-78 (2,000 trypomastigotes per kg body weight). Fol-
lowing inoculation, samples of blood were collected daily (from day 1 to
day 42) by venipuncture of the ear veins of infected dogs. The numbers of
parasites in the blood samples were determined under an optical micro-
scope, according to the method described by Brenner (32), and para-
sitemia curves were plotted using the daily mean numbers of parasites.
The production of T. cruzi-specific IgG antibodies in the infected animals
was determined by ELISA using total T. cruzi antigens. Sera of T. cruzi-
infected dogs were obtained from previous projects that evaluated the
immune responses in these infected animals (33, 34).
Sequence analysis andmapping of B-cell epitopes. The process of in
silico analysis of L. infantum hypothetical proteins consisted of two steps,
(i) the search for similarity among sequences deposited in nonredundant
protein databases and (ii) comparison with the genomes of other trypano-
somatids whose genomes have been sequenced completely or are in the
phase of annotation, i.e., Leishmania major, Leishmania mexicana, Leish-
mania braziliensis, Trypanosoma cruzi, and Trypanosoma brucei (all avail-
able at www.genedb.org). The sequences of the 26 hypothetical proteins
were mapped using the BepiPred program (http://www.cbs.dtu.dk
/services/BepiPred) (35) and the algorithm described by Kolaskar and
Tongaonkar to identify antigenic determinants in proteins (http://tools
.immuneepitope.org/tools/bcell/iedb_input) (36). B-cell peptides that
were matched by the 2 programs simultaneously were selected and syn-
thesized by GenScript. The lyophilized peptides were diluted in Milli-Q
water (Millipore) for use in the experiments.
ELISA. Previous titration curves were performed to determine the
most appropriate antigen concentration and antibody dilution to be used.
Falcon flexible microtiter immunoassay plates (Becton, Dickinson) were
coated with individual peptides (each at 1.0 g/well) in 50 l of Milli-Q
water for 18 h at 37°C or SLA (2.0g/well) in 100l of coating buffer (pH
9.6) for 18 h at 4°C. After sensitization, free binding sites were blocked for
1 h at 37°C using 200l of a solution composed of PBS and 0.05% Tween
20 (PBST) and containing 5% casein. After the plates had been washed five
times using PBST, they were incubated with 100 l of canine serum for 1
h at 37°C. Samples were diluted 1:100 (for peptide ELISA) or 1:200 (for
SLA ELISA) in PBST containing 0.5% casein. Plates were washed seven
times using PBST and were incubated with an anti-dog IgG horseradish
peroxidase-conjugated antibody (1:10,000; Sigma, St. Louis, MO) for 1 h
at 37°C. After seven washes with PBST, the reaction was developed
through incubation with H2O2, ortho-phenylenediamine, and citrate
phosphate buffer (pH 5.0) for 30 min in the dark. The reaction was
stopped by adding 25l of 2 N H2SO4, and the optical density was read in
an ELISA microplate spectrophotometer (SpectraMax Plus; Molecular
Devices, Canada), at 492 nm.
Data analysis. All of the statistical analyses were performed using
GraphPad Prism (version 5.0 for Windows). The cutoff values for assess-
ing the sensitivity and specificity of synthetic antigens were determined
using receiver operating characteristic (ROC) analysis, and the area under
the curve (AUC) was calculated to assess the accuracy of the tests. First,
ROC curves were plotted with values for healthy control dogs versus val-
ues for symptomatic CVL dogs (all peptides). Cutoff values were chosen
to obtain a minimum of 95% specificity. Second, ROC curves were plotted
with values for T. cruzi-infected dogs versus values for symptomatic CVL
and values for healthy control dogs versus values for asymptomatic CVL
(selected peptides; see Table 3). The cutoff values for each peptide were
those obtained in the previous analysis (see Table 2). Then, sensitivity,
specificity, and AUC values were assessed. The same procedure was ad-
opted to assess the sensitivity, specificity, and AUC values for synthetic
antigen mixes.
RESULTS
Peptide identification. In the present work, 8 of 26 previously
identified hypothetical proteins were recognized as Leishmania-
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specific antigens by database searches (Table 1). The other 18 pro-
teins presented primary sequences similar to those of proteins of
T. cruzi and/or T. brucei species and were not evaluated in this
study. The 8 selected proteins were mapped in silico to predict the
B-cell-specific epitopes, and a total of 17 peptides were identi-
fied and synthesized. The sequences of the peptides were AAVC
VAAALYAL (PepLi1), AGQSVPNSL (PepLi2), CTECDTGYSLTS
DYQCKAITT (PepLi3), FTVTRDVTMSSTSFDDYTMVLDLS
(PepLi4), SGALFSFPAGLEDASE (PepLi5), TMMPDTPSADASP
SPRITRI (PepLi6), GTSAVYERYLLLTP (PepLi7), KLLFPLPPPP
LRLPEALQELSPECH (PepLi8), VLVAAAALVIAAEQLRMPLPA
(PepLi9), SGPGAGAAL (PepLi10), QGPPPLASV (PepLi11), SVL
KGYQALKQSTAGSD (PepLi12), QEEAEEEEAAAVAGSAQPHP
(PepLi13), DMVALQEEAKSVRDRRLALEEIMR (PepLi14), DK
KQKAREERFAASLQRRLERRKA (PepLi15), PVEAVEEAVAT
(PepLi16), and QPQQPVTQQPVYQPPPPMEPV (PepLi17).
ELISA. The synthetic peptides were then employed as antigens
in ELISA to compare their diagnostic performance, using sera
from L. infantum-infected dogs and healthy animals. Of the 17
peptides, 6 (namely, PepLi1, PepLi2, PepLi3, PepLi6, PepLi7, and
PepLi15) presented sensitivity and specificity values of 90%
and95%, respectively, in identifying L. infantum-infected dogs
(Table 2). In this context, these 6 peptides were selected for the
next phase of experiments in which their sensitivity and specificity
were investigated using 20 serum samples from asymptomatic
CVL dogs and 19 serum samples from T. cruzi-infected animals
(Table 3). Of these evaluated antigens, PepLi1, PepLi2, and PepLi7
presented sensitivity values of 100%, 100%, and 93% and speci-
ficity values of 95%, 93%, and 95%, respectively. In a comparison
of serum samples from asymptomatic and healthy dogs, the sen-
sitivity values were 75%, 100%, and 75% and the specificity values
were 72%, 96%, and 96% for PepLi1, PepLi2, and PepLi7, respec-
tively.
Peptidemix for theCVLdiagnosis. Finally, the 3 selected pep-
tides were combined in different mixtures to evaluate their diag-
TABLE 1 Number of trypanosomatide sequences exhibiting similarity
to hypothetical proteins selected from Leishmania infantum
GenBank
accession no.
No. of sequences with similarity to:
L. braziliensis L. major L. mexicana T. cruzi T. brucei
XP_888524.1 4 5 1 NDa ND
XP_001463134.1 1 1 1 ND ND
XP_001466114.1 1 1 1 ND ND
XP_001467567.1 1 1 1 ND ND
XP_001468309.1 1 1 1 ND ND
XP_001564657.1 1 1 1 ND ND
XP_001568117.1 1 1 1 ND ND
XP_001686061.1 1 1 1 ND ND
XP_001568364.1 1 1 1 1 1
XP_001568689.1 1 1 1 1 1
XP_001567688.1 1 1 1 ND 2
XP_001466647.1 1 1 1 ND 2
XP_001467784.1 1 1 1 ND 2
XP_001564693.1 1 1 1 2 ND
XP_001465588 1 1 1 2 ND
XP_001565846.1 1 1 1 2 2
XP_001467126.1 1 1 1 2 2
XP_001564596.1 1 1 1 2 2
XP_843545.1 1 1 1 2 2
XP_001469969.1 1 1 1 2 2
XP_001468941.1 1 1 1 2 2
XP_001682223.1 1 1 1 2 2
XP_001463668.1 1 1 1 2 2
XP_001684096.1 1 1 1 2 2
XP_001684884.1 1 1 1 2 2
CAJ09012.1 1 1 1 2 2
a ND, not detected.
TABLE 2 Diagnostic performance of selected peptides using sera from symptomatic CVL dogs and serologically negative dogsa
GenBank accession no. Peptide Sensitivity (% [95% CIb]) Specificity (% [95% CI]) AUC
XP_888524.1 PepLi1 100 (69.00–100) 95.00 (75.10–99.90) 1
PepLi2 100 (69.00–100) 95.00 (74.00–99.90) 1
PepLi3 93.00 (68.00–99.80) 96.00 (79.70–99.90) 0.9307
PepLi4 67.00 (38.40–88.20) 96.00 (79.70–99.90) 0.8373
PepLi5 53.00 (26.60–78.70) 96.00 (79.70–99.90) 0.8653
XP_001463134.1 PepLi6 100 (78.20–100) 96.00 (79.70–99.90) 0.9840
PepLi7 90.00 (55.50–99.80) 95.00 (75.10–99.90) 1
XP_001466114.1 PepLi8 87.00 (59.50–98.30) 96.00 (79.70- 99.90) 0.9387
PepLi9 73.00 (44.90–92.20) 96.00 (79.70–99.90) 0.9520
PepLi10 53.00 (26.60–78.70) 96.00 (79.70–99.90) 0.9067
PepLi11 47.00 (21.30–73.40) 96.00 (79.70- 99.90) 0.9147
XP_001467567.1 PepLi12 47.00 (21.30–73.40) 96.00 (79.70–99.90) 0.6053
XP_001468309.1 PepLi13 67.00 (38.40–88.20) 96.00 (79.70–99.90) 0.9027
XP_001564657.1 PepLi14 73.00 (44.90–92.20) 96.00 (79.70–99.90) 0.9173
XP_001568117.1 PepLi15 93.00 (68.10–99.80) 96.00 (79.70–99.90) 1
PepLi16 67.00 (38.40–88.20) 96.00 (79.70–99.90) 0.8533
XP_001686061.1 PepLi17 27.00 (7.80–55.10) 96.00 (79.70–99.90) 0.7467
SLAc 100 (78.20–100) 96.00 (79.70–99.90) 1
a Samples from symptomatic L. infantum-infected dogs (n 25) and animals with no clinical signs of CVL and negative parasitological and serological results for Leishmania
antigens (n 40) were tested in ELISA. Receiver operating characteristic (ROC) curves were used to determine sensitivity, specificity, and AUC values.
b CI, confidence interval.
c SLA, soluble Leishmania infantum antigen extract.
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nostic performance in serological tests by ELISA. In this context,
the different mixtures were composed as follows: mix 1, PepLi
plus PepLi2; mix 2, PepLi1 plus PepLi7; mix 3, PepLi2 plus PepLi7;
mix 4, PepLi1 plus PepLi2 plus PepLi7. Figure 1 shows the results
of the individual distribution of the serum samples in relation to
the different peptide mixtures. When the sensitivity of the differ-
ent mixtures to differentiate among the serum samples of symp-
tomatic L. infantum-infected and healthy dogs was evaluated, mix
1, mix 2, mix 3, and mix 4 presented sensitivities of 100%, 100%,
80%, and 95%, respectively (Fig. 2). Regarding the specificity to
differentiate the serum samples of symptomatic L. infantum-in-
fected dogs from those of T. cruzi-infected animals, the mixtures
presented values of 100%, 100%, 76%, and 95% for mix 1, mix 2,
mix 3, and mix 4, respectively (Table 4).
DISCUSSION
Serological tests are currently recommended for the laboratory
diagnosis of CVL. IFAT and ELISA are the most widespread diag-
nostic assays applicable to leishmaniasis; however, their low sen-
sitivity to detect cases with low or absent levels of Leishmania-
TABLE 3 Diagnostic performance of selected peptides using other serum samplesa
Peptide
T. cruzi-infected vs symptomatic dogs Control vs asymptomatic dogs
Sensitivity (%) Specificity (%) AUC Sensitivity (%) Specificity (%) AUC
PepLi1 100 95.00 1 75.00 72.00 0.51
PepLi2 100 93.00 1 100 96.00 1
PepLi3 60.00 95.00 0.88 30.00 92.00 0.56
PepLi6 53.00 95.00 0.79 70.00 96.00 0.86
PepLi7 93.00 95.00 0.97 75.00 96.00 0.75
PepLi15 40.00 95.00 0.63 45.00 96.00 0.89
SLAb 100 36.00 0.95 4.00 100 0.56
a Samples from T. cruzi-infected dogs (n 19), asymptomatic (n 20) and symptomatic (n 25) L. infantum-infected dogs, and animals with no clinical signs of CVL and
negative parasitological and serological results for Leishmania antigens (n 40) were used. Receiver operating characteristic (ROC) curves were used to determine ELISA
sensitivity, specificity, and AUC values.
b SLA, soluble Leishmania infantum antigen extract.
FIG 1 Evaluation of ELISA reactivity using peptide mixtures with different serum samples. ELISAs were performed using serum samples from T. cruzi-infected
(n 19), asymptomatic (n 20) and symptomatic (n 25) L. infantum-infected, and healthy (n 40) dogs. Reactions against mix 1 (A), mix 2 (B), mix 3 (C),
and mix 4 (D) are shown. Mixes were as follows: mix 1, PepLi1 plus PepLi2; mix 2, PepLi1 plus PepLi7; mix 3, PepLi2 plus PepLi7; and mix 4, PepLi1 plus PepLi2
plus PepLi7. O.D., optical density.
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specific antibodies and their cross-reactivity with other diseases,
including Chagas’ disease, represent important limitations for
their use in laboratory serodiagnosis (37). Moreover, crude anti-
gens also are limited by the difficulty of producing large quantities
in a standardized manner (30).
Improvements in sensitivity and specificity might be achieved
by using individual Leishmania proteins that are recognized by
sera from L. infantum-infected dogs. After database searches were
performed in this study, eight antigens were identified as Leishma-
nia-specific proteins. Since they were recognized by sera from L.
infantum-infected dogs in a previous immunoproteomics study
(29), their primary sequences were mapped to obtain B-cell-spe-
cific epitopes, which were synthesized and subsequently evaluated
as new and more-refined antigens for a more sensitive and specific
serodiagnosis of L. infantum infections in dogs.
The specificity of ELISA using SLA depends heavily on antigen
preparation. Many times, false-positive results are obtained when
serum samples are collected from animals with other diseases,
such as Chagas’ disease (22, 38). Recombinant leishmanial anti-
gens also have been tested with ELISA to develop a more specific
test (25); although their specificity is generally greater, sensitivity
is hampered, given the much lower availability of B-cell epitopes
than for SLA and the high level of heterogeneity of major histo-
compatibility complex (MHC) molecules of canine populations
(39).
Among the tested synthetic antigens, PepL1, PepL2, PepL3,
FIG 2 Diagnostic performance of peptide mixtures with different serum samples. Samples from T. cruzi-infected (n  19), symptomatic CVL (n  25), and
healthy (n  40) dogs were used. Receiver operating characteristic (ROC) curves were used to determine ELISA sensitivity, specificity, and AUC values, and
sensitivity and specificity values for the different mixtures with serum samples from T. cruzi-infected, symptomatic CVL, and healthy dogs are shown. The mixes
were as follows: mix 1, PepLi plus PepLi2; mix 2, PepLi1 plus PepLi7; mix 3, PepLi2 plus PepLi7; and mix 4, PepLi1 plus PepLi2 plus PepLi7.
TABLE 4 Diagnostic performance of peptide mixes using different serum samplesa
Mix
Control vs symptomatic dogs Control vs asymptomatic dogs T. cruzi-infected vs symptomatic dogs
Sensitivity (%) Specificity (%) AUC Sensitivity (%) Specificity (%) AUC Sensitivity (%) Specificity (%) AUC
1 100 100 1 20.00 100 0.96 100 100 1
2 100 100 1 0 95.00 0.52 100 94.00 1
3 80.00 100 1 0 95.00 0.63 76.00 100 1
4 95.00 100 1 70.00 97.50 0.96 95.00 88.00 0.98
a Samples from T. cruzi-infected dogs (n 19), symptomatic (n 25) and asymptomatic (n 20) visceral leishmaniasis dogs, and animals with no clinical signs of CVL and
negative parasitological and serological results for Leishmania antigens (n 40) were used. ROC curves were used to determine ELISA sensitivity, specificity, and AUC values.
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PepL6, PepL7, and PepL15 showed the highest sensitivities (100%,
100%, 93%, 100%, 90%, and 93%, respectively) and specificities
(95%, 95%, 96%, 96%, 95%, and 96%, respectively). In canine
epidemiological screening, a test with high sensitivity and speci-
ficity is desirable. The performance observed for the synthetic an-
tigens in this work is consistent with the performance of many
antigens (mainly recombinant proteins) that have been developed
in recent years for CVL diagnosis by ELISA (23, 24), with the
advantages of being cheaper, simpler, reproducible, useful for
large-scale testing and, in most cases, more specific and sensitive
(26). Our results show an improvement in the sensitivity of the
synthetic antigen ELISA, compared to the indirect immunofluo-
rescence assay, in asymptomatic dogs, due to the fact that the IFAT
shows a lack of sensitivity for the detection of specific antibodies in
asymptomatic dogs (20) and in healthy dogs, due to the large
number of false-positive IFAT reactions (18). It should be taken
into account that the ELISA technique allows better interpretation
of the results than IFAT, because in that technique the interpreta-
tion is subjective and depends on the expertise of the operator.
Multiple-epitope chimeric antigens have been evaluated as
markers for the serodiagnosis of CVL (25, 40). In an attempt to
improve sensitivity and specificity and to avoid cross-reactions,
we prepared antigenic mixtures of the synthetic antigens that
showed the best results and tested them by ELISA. All of the mix-
tures containing the synthetic antigens, i.e., mix 1, mix 2, mix 3,
and mix 4, showed high sensitivities (100%, 100%, 80%, and 95%,
respectively) and specificity (100% in all cases), as well as a perfect
accuracy (AUC  1) when tested in discriminating dogs with
symptomatic CVL from healthy animals. When tested in discrim-
inating between dogs with symptomatic visceral leishmaniasis and
T. cruzi-infected dogs, mix 1, mix 2, and mix 4 showed high sen-
sitivities (100%, 100, and 95%, respectively), while mix 3 showed
a sensitivity of 76%. All of the mixes showed high specificities
(100%, 94%, 100%, and 88%, respectively).
The detection of asymptomatic L. infantum-infected dogs is
considered crucial in epidemiological studies, for laboratory diag-
nosis of the disease. A cohort study showed that the majority of
seronegative animals became positive in parasitological tests a few
months after presenting serological conversion to Leishmania an-
tigens (13). In addition, in experimentally infected dogs, diagnosis
was possible as early as 45 days postinfection and before the ani-
mals become seropositive. In this context, the diagnostic elucida-
tion of asymptomatic cases would contribute to better character-
ization of the epidemiology of CVL and evaluation of control
actions. Surprisingly, mix 2 and mix 3 failed to discriminate
asymptomatic CVL dogs from healthy dogs, while mix 1 and mix
4 showed sensitivities of 20% and 70% and specificities of 100%
and 97.5%, respectively. Recently, Costa et al. (27) performed ELI-
SAs using single and mixed synthetic antigens from previously
evaluated proteins, which showed high sensitivity in serum sam-
ples with low (95%) and intermediate (95%) antibody titers and
high specificity (95%); the capacities of these synthetic antigen
mixtures were not assayed against asymptomatic dogs, and cross-
reactivity assays were not performed. In addition, Faria et al. (28)
performed ELISAs using a mixture of synthetic antigens and ob-
tained high sensitivity and specificity values (78.5% and 80%, re-
spectively), but all of the synthetic antigens and the mixture ex-
hibited high cross-reactivity with T. cruzi serum samples.
The serum samples used in this work did not contain samples
from dogs infected with other Leishmania species, such as L. bra-
ziliensis; the collection of sera from dogs was restricted to the ur-
ban area of Belo Horizonte (Minas Gerais, Brazil), where a low
incidence of infection with L. braziliensis in dogs was noted re-
cently (41). In addition, the sample size used in this work was
limited and follow-up evaluation of the asymptomatic dogs was
not performed. Thus, our data should be taken as a proof of con-
cept of the capacity of the proposed synthetic antigens for the
diagnosis of CVL and might serve as a reference for further assays.
Taken together, the results presented here demonstrate that
the 3 synthetic peptides obtained from previously selected hypo-
thetical proteins might be considered an interesting alternative for
a more sensitive and specific serodiagnosis of CVL, when used in
an isolated or multiple-epitope chimeric mixture format in sero-
logical testing by ELISA. This study can be considered relevant
mainly in identifying seronegative animals without clinical signs
but with positive molecular results for L. infantum, represented
here as asymptomatic dogs, in epidemiological studies and/or ar-
eas in which CVL is endemic.
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